Through diligent and long-term thinking, and building bridges and trust with stakeholders, we have established a close partnership with patient organisations and several new modes of…
In Conversation
Through the acquisition and integration of Algeta, Bayer’s Norwegian operations have become one of the company’s global R&D and innovation hubs for radiopharmaceuticals. Radiopharmaceuticals in Norway,…
What our members want is a good and stable relationship with their most important trading partners, top among which is the EU
Culture eats strategy for breakfast – you can have the best strategy but if you do not work with the right culture or adjust to the…
Driving forward digital transformation is one of Bayer’s strategic priorities as we believe digitalization in healthcare has the potential to achieve game-changing efficiencies and drive a…
We need to try and make sure that we are following the science [on COVID-19 vaccines] very closely, and refrain from getting lost in all the…
The challenge for the future of innovation in Switzerland and for Swiss pharma companies in general is to once again adapt to technological changes
Whereas previously vaccines were a little out of fashion, and the sector was rather dusty and forgotten, now, people can see the importance of vaccine R&D…
[Norway] should stop thinking that we should only be the best in the world at oil and gas. We should do as they have done in…
In 2019 Switzerland exported more to the US than to France, Italy, UK and Austria combined and twice as much as Brazil, Russia, India and China…
Norway has unfulfilled innovation potential. There is a lot to be gained from an environment where pharmaceutical companies, research groups and clinicians can interact
We are trying to do fund both open research, where it is the researchers who define the research questions, as well as areas where we see…
